The use of these combined therapies was shown to be a good therapeutic option to either prevent or overcome resistance to TAM in cancers overexpressing epidermal growth factor receptor (EGFR) or EGFR2 (HER2) [18,19,20,21]. Here, EGFR is linked to cancer.